Breaking News

Eurofins Acquires Merck KGaA’s DDS Business

By Kristin Brooks | January 9, 2014

Expands presence in discovery pharmacology and bioanalysis

Eurofins Scientific has signed an agreement to acquire the assets of the Discovery and Development Solutions (DDS) business of Merck Millipore (EMD Millipore), the Life Science division of Merck KGaA. DDS provides bioanalytical testing and early stage discovery services and products to the biopharmaceutical industry and generates revenues of approximately $35 million with 175 employees from three sites in St. Charles, MO, Dundee, Scotland and Oxford, England.
DDS also provides expertise in bioanalytical testing to support clinical trials. The acquisition expands Eurofins' capabilities in early stage discovery solutions and adds expertise in high-quality bioanalytical services. DDS will continue to provide products and services to Merck KGaA's pharma business.
Eurofins will retain DDS' workforce and leadership, and the business will continue to be led by Christina Shasserre, who will serve as president of the new company, Eurofins Pharma BioAnalytical Services, following the closing. The transaction, subject to standard closing conditions, is expected to be complete within 90 days.
Dr. Gilles Martin, Eurofins chief executive officer, said, "The addition of DDS into the Eurofins network reinforces our leading position in the discovery pharmacology market, and expands our large molecules bioanalytical service capability to meet the growing needs of our pharmaceutical and biopharmaceutical clients. The transaction reflects Eurofins' commitment to provide the best laboratory services and client support to its customers, and the highest level of analytical testing technology available in the industry."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.